InCarda Therapeutics
Brisbane, US · Founded 2009 · Delaware corporation · 11 employees on LinkedIn · 6 known investors
Find your way into InCarda Therapeutics
1,547 people in our graph share verified history with the InCarda Therapeutics team — schools, employers, funds. One of them is your warm intro.
Stephane Kurganunlockedknows Grace Colon · together at McKinsey & Company (overlapped)
×4knows the team · via McKinsey & Company
×3knows the team · via University of California, Berkeley
×2knows the team · via Massachusetts Institute of Technology
knows the team · via Santa Clara University
knows the team · via New Science Ventures
Incardatherapeutics develops drug therapies for treating atrial fibrillation using synergistic combinations of anti-arrhythmic agents, with delivery platforms designed for both hospital and at-home settings. The company targets reducing the clinical and economic burden of atrial fibrillation in the U.S. healthcare system.
Founders & leadership
InCarda Therapeutics was founded in 2009 by Carlos A. Schuler and John S. Patton.
CA
Carlos A. SchulerinChief Technology Officer and Co-founderCarlos A. Schuler is Executive Officer and Director at InCarda Therapeutics, which develops drug therapies for treating atrial fibrillation. He brings over 30 years of cross-functional engineering and management experience.
JS
John S. PattoninCo-founder, Executive Chairman2008–2015John S. Patton co-founded Inhale (later Nektar Therapeutics) in 1990, which developed inhaled insulin delivery technology and reached a $2.1 billion valuation on NASDAQ in 2001, and has since founded or co-founded multiple drug development companies including Dance Biopharm, InCarda Therapeutics, iPharma, and Tesio Pharmaceuticals, focusing on novel delivery platforms and therapeutic agents across cardiovascular, respiratory, and inflammatory indications.
RN
Rangachari NarasimhanExecutive
GC
Grace ColoninAdvisor2022–2023
MS
Miller SamanthaExecutive
Board
MR
McCarthy ReenieBoard director
BN
Bischofberger NorbertBoard director
Investors · 6
Asset Management CompanyMenlo Park · $500K – $2M
HealthCapStockholmvia Johan Christenson · board
Sofinnova VenturesMenlo Park · $100K – $15M
Deerfield Management Companyreported · 2 sourcesNew Yorkvia Andrew ElBardissi · board
Also in the syndicate · 2
InnovivaleadMorningside Ventures
Reported raises · per SEC filings
Form D private placements$66M disclosed across 4 rounds · 2013–2020
▶$28MraisedOct 2020 · 5 investors · PharmaceuticalsRule 506(b)
▶$28MraisedOct 2020 · 5 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Andrew ElBardissiDirector
- Johan ChristensonDirector
- Alan ColowickDirector
- Isaac ChengDirector
- Grace ColonExecutive Officer, Director
- Dan WelchDirector
- Offering amount
- $50M
- Amount sold
- $28M
- First sale
- Oct 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$35.3MraisedNov 2019 · 24 investors · PharmaceuticalsRule 506(b)
▶$35.3MraisedNov 2019 · 24 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Grace ColonExecutive Officer, Director
- Isaac ChengDirector
- Bischofberger NorbertDirector
- Alan ColowickDirector
- Johan ChristensonDirector
- Andrew ElBardissiDirector
- Dan WelchDirector
- Offering amount
- $42.1M
- Amount sold
- $35.3M
- Minimum investment
- $1.8K
- First sale
- Oct 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.1MraisedMay 2017 · 16 investors · PharmaceuticalsRule 506(b)
▶$2.1MraisedMay 2017 · 16 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Rangachari NarasimhanExecutive Officer, Director
- McCarthy ReenieDirector
- Grace ColonExecutive Officer, Director
- Bischofberger NorbertDirector
- Miller SamanthaExecutive Officer
- Offering amount
- $2.5M
- Amount sold
- $2.1M
- Minimum investment
- $5K
- First sale
- Mar 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$567KraisedDec 2014 · 13 investors · PharmaceuticalsRule 506(b)
▶$567KraisedDec 2014 · 13 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Grace ColonExecutive Officer, Director
- Carlos A. SchulerExecutive Officer, Director
- Rangachari NarasimhanExecutive Officer, Director
- John S. PattonExecutive Officer, Director
- Offering amount
- $12.9M
- Amount sold
- $567K
- First sale
- Sep 2013
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlap
Cardurion6 shared keywordsCardurion is a cardiovascular disease-focused company developing therapeutics, with a pipeline advanced through clinical development, trial design, regulatory affairs, and commercialization. It draws on a board of cardiovascular disease experts and industry veterans to guide its drug development.
AltaThera Pharmaceuticals6 shared keywordsAltaThera develops intravenous antiarrhythmic therapies for treating cardiac conditions including atrial fibrillation and ventricular tachycardia. The company's lead product, Sotalol IV, enables faster patient assessment and potential outpatient discharge compared to oral alternatives.
Companies competing with InCarda Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does InCarda Therapeutics do?
- Incardatherapeutics develops drug therapies for treating atrial fibrillation using synergistic combinations of anti-arrhythmic agents, with delivery platforms designed for both hospital and at-home settings. The company targets reducing the clinical and economic burden of atrial fibrillation in the U.S. healthcare system.
- Who founded InCarda Therapeutics?
- InCarda Therapeutics was founded by Carlos A. Schuler, John S. Patton in 2009.
- Who are InCarda Therapeutics's investors?
- InCarda Therapeutics's investors include Asset Management Company, HealthCap, Sofinnova Ventures, Deerfield Management Company.
- How much funding has InCarda Therapeutics raised?
- InCarda Therapeutics has disclosed $66M raised across 4 rounds.
- Where is InCarda Therapeutics headquartered?
- InCarda Therapeutics is headquartered in Brisbane, US.